The global ATTR amyloidosis treatment market size is estimated to touch USD 4.14 Billion in 2025. It is forecasted to reach a valuation of USD 7.52 Billion by 2032, by exhibiting a CAGR of 8.9% throughout the forecast period (2025-2032).
Amyloid transthyretin (ATTR) is a disorder caused by the misfolding of the transthyretin protein. This misfolding causes a buildup of amyloid fibrils in organs and tissues, impairing their function and ultimately leading to their decay.
The ATTR amyloidosis treatment market is expected to scale owing to the rising prevalence of the disease, coupled with the use of AI-based screening tools for earlier detection. Clinical trials showcasing success in gene editing techniques can propel the market growth over the forecast period.
But the high costs of treatment can impede the market growth.
Key Market Insights
The ATTR amyloidosis treatment market is anticipated to be influenced by improvements in imaging systems and increased awareness of the disease.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/attr-amyloidosis-treatment-market
ATTR Amyloidosis Treatment Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 4.14 Billion |
|
Estimated Value by 2032 |
USD 7.52 Billion |
|
Growth Rate |
8.9% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The availability of disease-modifying therapies, such as stabilizers and silencers, can significantly drive the market growth by curtailing the formation of amyloids. This is fueled by the approval of various drugs targeting key processes involved in the formation, deposition, and elimination of amyloid fibrils.
The role of genetic testing is expected to become crucial for the accurate indications of ATTR. This can extend to at-risk family members and lead to early diagnosis of the disease. Bone scintigraphy, echocardiography with strain imaging, cardiac MRI, and the use of biomarkers like NT-proBNP are diagnostic tools that can prevent organ damage and effectively bolster the market growth.
Market Opportunity
Specialized Cardiac Treatments
The prevalence of amyloid transthyretin cardiomyopathy (ATTR-CM) is expected to present a lucrative market opportunity. This can be attributed to the approval of RNA interference (RNAi) agents like AMVUTTRA that can reduce the mortality rate in cardiac cases. Moreover, the emergence of targeted therapies focusing on cardiology can bode well for the ATTR amyloidosis treatment market.
Market Challenge
Diagnosis Challenges Due to Similarity with Common Medical Conditions
The clinical overlap of ATTR with other common medical conditions can pose a challenge to the market growth. Recent analyses have noted a delay in the diagnosis of ATTR due to patients presenting with non-specific symptoms. The lack of therapeutic intervention owing to misdiagnosis and the high costs of pre-diagnosis such as advanced imaging and biopsy can restrict the market growth.
Analyst’s View
Recent Developments
Alnylam Pharmaceuticals’ AMVUTTRA (vutrisiran) was granted approval from the European Commission on June 09, 2025. It can be used in the treatment of cardiomyopathy caused by wild-type ATTR amyloidosis.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :